Full text is available at the source.
Type I interferon may reduce mRNA vaccine effectiveness by lowering antigen uptake in key immune cells
Updated
Abstract
Essence
Type I interferon signaling before mRNA-LNP vaccination may blunt dendritic-cell antigen uptake and weaken CD8+ T cell responses.
Evidence
This preclinical vaccine-immunology study tested DC-specific IFNα/β receptor loss, transient IFNαR blockade, prior infection, and prior vaccination in dendritic-cell uptake, T cell priming, and tumor-control models.
Caveat
The evidence is mechanistic and preclinical, so the timing strategy is not yet shown to improve vaccine efficacy in human clinical settings.
Simplified
mRNA Technology